Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4

Phase 3

Completed

• Conditions: Pulmonary Embolism

• Registration Number: NCT01120535
• Lead Sponsor: Crux Biomedical

Brief Summary

The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05
• Study First Submitted: 2010-05-06
• Study First Submitted QC: 2010-05-10
• Study First Posted: 2010-05-11
• Primary Completion: 2011-06
• Study Completion: 2012-01
• Status Verified: 2012-02
• Last Update Submitted: 2014-06-26
• Last Update Posted: 2014-06-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Patient has a permanent or temporary risk of Pulmonary Embolism.
• Patient must provide informed consent At least one of the following conditions -
• Proven PE
• Recurrent PE despite adequate
• Contraindication to anticoagulation
• Inability to achieve/maintain therapeutic anticoagulation
• Iliocaval DVT
• Large, free-floating proximal DVT
• Massive PE treated with thrombolysis/thrombectomy
• Chronic PE treated with thrombectomy
• Protection during thrombolysis for iliocaval DVT
• PE with limited cardiopulmonary reserve
• Poor compliance with anticoagulation medication
• High risk of injury worsening on anticoagulation
• Multi-trauma patient with high risk of PE
• Surgical patients at high risk of PE
• Medical condition with high risk of PE Patients with a documented vena cava diameter of 17-28mm Patient has IVC anatomy suitable for infra-renal placement Patient is willing to be available for the appropriate follow up

Exclusion Criteria

• Age <18 years old

• Patient has any one of the following conditions:

  • Renal vein thrombosis
  • IVC thrombosis extending to the renal veins
  • Duplicate IVC
  • Gonadal vein thrombosis
  • Requires supra-renal placement

• Vena cava diameter of 17-28mm

• Uncontrolled infectious disease

• Risk of aseptic PE

• Uncontrolled coagulopathy

• Existing inferior vena cava filter implant

• Life expectancy less than 6 months

• Pregnant or planning a pregnancy in the next 6 months

• Condition that inhibits radiographic visualization of the IVC

• Known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol

• Known hypersensitivity to contract which cannot be pretreated

• Access vessels preclude same insertion of delivery system

• Participation in another drug or device trial

• Unable or unwilling to cooperate with study procedures or required follow-up visits

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Clinical Success	6 Months	Clinical Success is a composite endpoint consisting of technical success with freedom from pulmonary embolism, filter migration and device related events requiring intervention.

Secondary Outcome Measures

Name	Time	Method
Rates of complications related to vena cava filter use.	6 months

Trial Locations

Locations (3)

Royal Brisbane Womens Hospital; 🇦🇺 Brisbane, Australia

The Alfred Hospital; 🇦🇺 Melbourne, Australia

Auckland City Hospital; 🇳🇿 Auckland, New Zealand